Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes

FRANEK, E.; HALUZIK, M.; VARZIC, S.; Sargin, MEHMET; MACURA, S.; ZACHO, J.; Christiansen, J.

doi:10.1111/dme.12982

Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes

FRANEK E., HALUZIK M., VARZIC S. C. , Sargin M., MACURA S., ZACHO J., ...More

DIABETIC MEDICINE, vol.33, no.4, pp.497-505, 2016 (Peer-Reviewed Journal)

Publication Type: Article / Article
Volume: 33 Issue: 4
Publication Date: 2016
Doi Number: 10.1111/dme.12982
Journal Name: DIABETIC MEDICINE
Journal Indexes: Science Citation Index Expanded, Scopus
Page Numbers: pp.497-505

Abstract

AimTo evaluate the efficacy and safety of twice-daily insulin degludec/insulin aspart vs. twice-daily biphasic insulin aspart 30 in people with Type 2 diabetes mellitus who were naive to insulin.